Biotech Takes Innovative Approach To Raising Capital For Its Promising Anti-Cancer Drug
- 6 months ago
Dr. Vuong Trieu, CEO & Chairman of Oncotelic Therapeutics, Inc. was recently a guest on Benzinga’s All-Access.
Oncotelic is a biotechnology company focused on developing RNA therapeutics for hard-to-treat cancers. The company has extensive experience in the field and its lead candidate OT-101 has shown very positive results in trials.
Money in biotech is hard to come by these days and Oncotelic has taken an innovative approach to fundraising for the commercialization of OT-101. It has created a joint venture with GMP Biotechnology, Sapu Bioscience, which it plans to take public.
Oncotelic is a biotechnology company focused on developing RNA therapeutics for hard-to-treat cancers. The company has extensive experience in the field and its lead candidate OT-101 has shown very positive results in trials.
Money in biotech is hard to come by these days and Oncotelic has taken an innovative approach to fundraising for the commercialization of OT-101. It has created a joint venture with GMP Biotechnology, Sapu Bioscience, which it plans to take public.